Physician profile
Marc Dror Michaelson
NPI 1275523490
$56,566.52
in general payments reported to CMS, 2019-2025
9 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $15K · 2021: $18K · 2022: $4,470 · 2023: $2,305 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,919 · Food and Beverage: $227 · Travel and Lodging: $73.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,919.00 |
| Food and Beverage | $226.79 |
| Travel and Lodging | $73.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16,490.00 | 2020-2022 | |
| Eisai INC. | $15,783.27 | 2019-2022 | |
| Exelixis INC. | $10,115.12 | 2019-2021 | |
| Pfizer INC. | $8,958.51 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $4,219.62 | 2023-2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $900.00 | 2019 | |
| Comsort, INC | $100.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Michaelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.